Product Description
Alnylam was developing aln-pcs02, an intravenous drug, for the treatment of Elevated LDL-Cholesterol (LDL-C) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01437059)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alnylam
Company Location: CAMBRIDGE MA 02142
Company CEO: Yvonne L. Greenstreet
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01437059 |
ALN-PCS02-001 | P1 |
Completed |
Other |
2012-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|